News Releases
- Curis to Present at the 2013 Wells Fargo Securities Healthcare Conference
06/11/2013 - Curis Announces CUDC-427 (GDC-0917) Phase I Clinical Data Presented at ASCO 2013 Annual Meeting
06/03/2013 - Curis Announces Appointment of Mani Mohindru, Ph.D., as Vice President of Corporate Strategy and Investor Relations
05/31/2013 - Curis to Present at the Jefferies 2013 Global Healthcare Conference
05/30/2013 - Curis to Present at the Deutsche Bank 38th Annual dbAccess Health Care Conference
05/22/2013 - Curis Announces Presentation of CUDC-427 and Erivedge(R) Clinical Results at ASCO Annual Meeting
05/16/2013 - Curis Announces Approval of Erivedge(R) in Australia
05/10/2013 - Curis Reports First Quarter 2013 Financial Results
04/30/2013 - Curis Announces Erivedge(R) Receives Positive CHMP Opinion for Conditional Approval in European Union
04/26/2013 - Curis to Present at the Needham 12th Annual Healthcare Conference
04/24/2013 - Curis to Release First Quarter 2013 Financial Results and Hold Conference Call on April 30, 2013
04/23/2013 - Curis to Present at the BioCentury Future Leaders in the Biotech Industry Conference
03/29/2013 - Curis Announces Appointment of Kenneth Pienta, M.D., to Board of Directors
03/11/2013 - Curis to Present at the Roth Capital Partners 25th Annual Growth Stock Conference
03/11/2013 - Curis to Present at the Cowen and Company 33rd Annual Health Care Conference
02/25/2013 - Curis Reports Fourth Quarter and Year-End 2012 Financial Results
02/20/2013 - Curis Appoints Ali Fattaey, Ph.D., as President and Chief Operating Officer
02/19/2013 - Curis to Present at Upcoming Investor Conferences
02/15/2013 - Curis to Release Fourth Quarter and Year End 2012 Financial Results and Hold Conference Call on February 20, 2013
02/13/2013 - Curis Announces Dosing of First Patient in Phase I Clinical Trial of Dual PI3 Kinase and HDAC Inhibitor CUDC-907
01/24/2013 - Curis Announces Closing of $30 Million Secured Debt Financing
12/12/2012 - Curis to Present at the Oppenheimer 23rd Annual Healthcare Conference
12/06/2012 - Curis Announces U.S. Patent Issuance Covering HSP90 Inhibitor Debio 0932
12/06/2012 - Curis Announces Worldwide In-Licensing of IAP Inhibitor GDC-0917 From Genentech
11/28/2012 - Curis Announces $30 Million Secured Debt Financing to Support Development of Proprietary Pipeline
11/28/2012 - Curis to Present at Upcoming Investor Conferences
11/27/2012 - Curis Reports Third Quarter 2012 Financial Results
11/06/2012 - Curis to Release Third Quarter 2012 Financial Results and Hold Conference Call on November 6, 2012
10/30/2012 - Curis Achieves CUDC-907 Milestones Under Its Agreement With The Leukemia & Lymphoma Society
10/18/2012 - Curis Announces Dosing of First Patient in Phase I Clinical Trial of Oral Formulation of CUDC-101
10/02/2012 - Curis to Present at Upcoming Investor Conferences
09/04/2012 - Curis to Present at Upcoming Health Care and Investor Conferences
08/30/2012 - Curis and Debiopharm Announce Initiation of Phase I-II Clinical Study of HSP90 Inhibitor Debio 0932
08/15/2012 - Curis to Present at the 2012 Wedbush PacGrow Life Sciences Management Access Conference
08/08/2012 - Curis Reports Second Quarter 2012 Financial Results
08/02/2012 - Curis to Release Second Quarter 2012 Financial Results and Hold Conference Call on August 2, 2012
07/26/2012 - Curis Announces Publication of CUDC-907 Data in Clinical Cancer Research
06/25/2012 - Curis Announces Publication of Erivedge(TM) Data in the New England Journal of Medicine
06/07/2012 - Curis to Present at the Jefferies 2012 Global Healthcare Conference
05/30/2012 - Curis Announces Collaborators' Presentation of Erivedge(TM) and Debio 0932 Clinical Data at ASCO Annual Meeting
05/17/2012 - Curis Reports First Quarter 2012 Financial Results
05/08/2012 - Curis Announces Collaborator Roche's Submission of Erivedge(TM) for Registration With Australian Regulatory Authority
05/07/2012 - Curis to Release First Quarter 2012 Financial Results and Hold Conference Call on May 8, 2012
05/01/2012 - Curis to Present at the Deutsche Bank Securities 37th Annual Health Care Conference
04/30/2012 - Curis to Present at the BioCentury Future Leaders in the Biotech Industry Conference
04/13/2012 - Curis Presents Data on PI3K and HDAC Inhibitor CUDC-907 at AACR Annual Meeting 2012
04/04/2012 - Curis to Present at the 11th Annual Needham Healthcare Conference
03/28/2012 - Curis to Present at the Roth 24th Annual OC Growth Stock Conference
03/06/2012 - Curis to Present at the 32nd Annual Cowen and Company Health Care Conference
02/27/2012 - Curis to Present at the 2012 RBC Capital Markets' Healthcare Conference
02/21/2012 - Curis to Present at the Citi 2012 Global Healthcare Conference
02/17/2012 - Curis and Debiopharm Announce Initiation of Phase Ib Expansion Study of HSP90 Inhibitor Debio 0932
02/16/2012 - Curis Reports Fourth Quarter and Year-End 2011 Financial Results
02/08/2012 - Curis to Present at the 14th Annual BIO CEO & Investor Conference
02/06/2012 - Curis to Release Fourth Quarter and Year-End 2011 Financial Results and Hold Conference Call on February 8, 2012
02/01/2012 - Curis Announces FDA Approval of Erivedge(TM) (vismodegib) Capsule as First Treatment for Advanced Basal Cell Carcinoma
01/30/2012 - Curis Announces Collaborator Roche's Submission of Marketing Authorization Application for Vismodegib in Advanced Basal Cell Carcinoma
12/22/2011 - Curis to Present at the Oppenheimer & Company's 22nd Annual Healthcare Conference
12/06/2011 - Curis Announces Agreement with The Leukemia & Lymphoma Society to Develop CUDC-907 for Lymphoma and Multiple Myeloma
11/30/2011 - Curis Presents Data on PI3K and HDAC Inhibitor CUDC-907 at the 2011 AACR-NCI-EORTC Symposium
11/16/2011 - Curis Announces FDA Acceptance and Priority Review of NDA for Vismodegib as Treatment for Advanced Basal Cell Carcinoma
11/09/2011 - Curis Announces Appointment of Maurizio Voi, M.D. as Chief Medical and Chief Development Officer
11/08/2011 - Curis Reports Third Quarter 2011 Financial Results
10/27/2011 - Curis to Present at the 10th Annual BIO Investor Forum
10/18/2011 - Curis to Present at the BioCentury NewsMakers in the Biotech Industry Conference
10/17/2011 - Curis, Inc. Announces Appointment of Robert Martell, M.D., Ph.D. to its Board of Directors
09/15/2011 - Curis Announces Submission of New Drug Application by Collaborator Genentech for Vismodegib in Advanced Basal Cell Carcinoma
09/12/2011 - Curis to Present at the Rodman & Renshaw 13th Annual Healthcare Conference
09/02/2011 - Curis Announces Dosing of First Patient in Phase I CUDC-101 Head and Neck Cancer Combination Trial
08/16/2011 - Curis Reports Second Quarter 2011 Financial Results
07/28/2011 - Curis to Release Second Quarter 2011 Financial Results and Hold Conference Call on July 28, 2011
07/21/2011 - Curis Announces Presentation of Positive Vismodegib Pivotal Clinical Data in Advanced Basal Cell Carcinoma
06/20/2011 - Curis to Present at the Jefferies 2011 Global Healthcare Conference
05/27/2011 - Curis to Present at the 2nd Annual ThinkEquity Healthcare Conference
05/18/2011 - Curis Reports First Quarter 2011 Financial Results
04/28/2011 - Curis to Release First Quarter 2011 Financial Results and Hold Conference Call on April 28, 2011
04/21/2011 - Curis to Present at the 18th Annual Future Leaders in the Biotech Industry Conference
04/08/2011 - Curis Presentations Highlight Breadth of Targeted Cancer Platform at 102nd AACR Annual Meeting 2011
04/06/2011 - Curis Announces Investigator-Initiated Phase II Study Results Presented at 102nd AACR Annual Meeting 2011
04/04/2011 - Curis Announces Presentations at 102nd American Association for Cancer Research Annual Meeting 2011
03/30/2011 - Curis to Present at the 10th Annual Needham Healthcare Conference
03/29/2011 - Curis Announces Positive Results in Genentech Pivotal Phase II Clinical Trial of GDC-0449 in Advanced Basal Cell Carcinoma
03/21/2011 - Curis Reports Fourth Quarter and Year-End 2010 Financial Results
02/10/2011 - Curis to Present at the 13th Annual BIO CEO & Investor Conference
02/07/2011 - Curis to Release Fourth Quarter and Year-end 2010 Financial Results and Hold Conference Call on February 10, 2011
02/03/2011 - Curis Selects Dual Pi3 Kinase and HDAC Inhibitor CUDC-907 as Development Candidate
01/06/2011 - Curis to Present at Piper Jaffray 22nd Annual Healthcare Conference
11/23/2010 - Curis Presents CUDC-101 Phase I Clinical Data and CU-201 Preclinical Data at 22nd EORTC-NCI-AACR Symposium
11/18/2010 - Curis to Present CUDC-101 Phase I Clinical Data and CU-201 Preclinical Data at the 22nd EORTC-NCI-AACR Symposium
11/15/2010 - Curis Awarded $500,000 in Grants Under the Patient Protection and Affordable Care Act
11/02/2010 - Curis Reports Third Quarter 2010 Financial Results
10/28/2010 - Curis Announces Genentech's Initiation of Phase II Trial for GDC-0449 in Operable Basal Cell Carcinoma
10/11/2010 - Curis Provides Update on Genentech's Phase II Clinical Trial of GDC-0449 in Advanced Ovarian Cancer Patients
08/09/2010 - Curis Announces Dosing of First Patient in CUDC-101 Phase Ib Expansion Trial
08/03/2010 - Curis Reports Second Quarter 2010 Financial Results
08/03/2010 - Curis Achieves Phase I Milestone Under Hsp90 Collaboration with Debiopharm
07/06/2010 - Curis Announces Genentech's Phase II Clinical Trial Results of GDC-0449 in Combination with Avastin(R) and Chemotherapy in First-Line Metastatic Colorectal Cancer
06/16/2010 - Curis Announces Change to Presentation Time at ThinkEquity's Mid Year Check-up on Healthcare Conference
06/14/2010 - Curis, Inc. Announces Appointment of Marc Rubin, M.D. to its Board of Directors
06/04/2010 - Curis to Present at the Needham Healthcare Conference
06/03/2010 - Curis to Present at the Jefferies 2010 Global Life Sciences Conference
06/02/2010 - Curis Added to NASDAQ BiotechnologyIndex
05/19/2010 - Curis to Present at the Rodman & Renshaw 6th Annual Global Healthcare Conference
05/11/2010 - Curis Reports First Quarter 2010 Financial Results
05/06/2010 - Curis Completes Enrollment of CUDC-101 Phase I Clinical Trial
05/03/2010 - Curis to Release First Quarter 2010 Financial Results and Hold Conference Call on May 6, 2010
04/29/2010 - Curis Licensee Debiopharm Initiates Phase I Clinical Trial of Hsp90 Inhibitor Debio 0932
04/27/2010 - Curis Publishes Preclinical CUDC-101 Data in Cancer Research
04/22/2010 - Curis Presents Preclinical Data on CU-906 at AACR 101st Annual Meeting 2010
04/21/2010 - Curis to Present at the 17th Annual Future Leaders in the Biotech Industry Conference
04/01/2010 - Curis to Present at the ROTH Capital Partners 22nd Annual OC Growth Stock Conference
03/10/2010 - Curis to Present at the 30th Annual Cowen Healthcare Conference
03/02/2010 - Curis Reports Fourth Quarter and Year-End 2009 Financial Results
02/25/2010 - Curis to Present at the RBC Capital Markets Healthcare Conference
02/23/2010 - Curis to Release Fourth Quarter and Year-end 2009 Financial Results and Hold Conference Call on February 25, 2010
02/18/2010 - Curis Announces Chugai's Exercise of Japanese Development Rights for GDC-0449
02/18/2010 - Curis Achieves Milestone Under Hsp90 Collaboration with Debiopharm
02/12/2010 - Curis Publishes CUDC-101 Medicinal Chemistry Data
02/10/2010 - Curis to Present at the 12th Annual BIO CEO & Investor Conference
02/01/2010 - Curis, Inc. Announces $16.25 MillionRegistered Direct Offering
01/22/2010 - Curis Publishes Preclinical Data for Heat Shock Protein 90 Molecule in Erlotinib-Resistant Non-Small Cell Lung Cancer
12/04/2009 - Curis to Present at Piper Jaffray 21st Annual Healthcare Conference
11/25/2009 - Curis to Present at Lazard Capital Markets 6th Annual Healthcare Conference
11/11/2009 - Curis Reports Third Quarter 2009 Financial Results
10/29/2009 - Curis to Release Third Quarter 2009 Financial Results and Hold Conference Call on October 29, 2009
10/22/2009 - Curis to Present at the 8th Annual BIO Investor Forum
10/21/2009 - Curis to Present at Maxim Group Growth Conference 2009
09/22/2009 - Curis Announces GDC-0449 Phase I Clinical Data Published in New England Journal of Medicine
09/03/2009 - Curis to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
09/02/2009 - Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305
08/06/2009 - Curis Reports Second Quarter 2009 Financial Results and Provides Pipeline Update
07/30/2009 - Curis to Release Second Quarter 2009 Financial Results and Hold Conference Call on July 30, 2009
07/23/2009 - Curis Added to Russell 3000® and Russell 2000® Indexes
06/29/2009 - Curis Announces Issuance of U.S. Patent Covering CUDC-101 Composition of Matter for Novel HDAC/EGFR/Her2 Inhibitor
06/17/2009 - Curis Publishes Preclinical Data for Heat Shock Protein 90 Molecule CUDC-305 in Clinical Cancer Research
06/10/2009 - Curis to Present at the 8th Annual Needham Life Sciences Conference
06/04/2009 - Curis to Present at the Leerink Swann
Novel Cancer Therapeutics Roundtable Conference
05/13/2009 - Curis Reports First Quarter 2009 Financial Results
05/05/2009 - Curis to Release First Quarter 2009 Financial Results and Hold Conference Call on May 5, 2009
04/28/2009 - Curis Presents Preclinical Data for CU-903 at Keystone Symposia Event “PI3 Kinase Signaling in Disease”
04/27/2009 - Curis Presents CUDC-305 Preclinical Data at the AACR 100th Annual Meeting 2009
04/22/2009 - Curis announces presentations at American Association for Cancer Research Annual Meeting 2009
04/09/2009 - Curis to Present at the Barclays Capital Global Healthcare Conference
03/11/2009 - Curis to Present at the Barclays Capital Global Healthcare Conference
03/04/2009 - Curis Announces Genentech’s Initiation of Pivotal Phase II Trial of GDC-0449 in Advanced Basal Cell Carcinoma
02/12/2009 - Curis Reports Fourth Quarter and Year-End 2008 Financial Results
02/10/2009 - Curis Announces Collaborative Agreement between Genentech and National Cancer Institute on GDC-0449
02/09/2009 - Curis to Present at the 11th Annual BIO CEO Investor Conference
02/04/2009 - Curis to Release Fourth Quarter and Year-end 2008 Financial Results and Hold Conference Call on February 10, 2009
02/03/2009 - Curis Announces Genentech’s Expected Initiation of Pivotal Phase II Trial in Advanced Basal Cell Carcinoma with Hedgehog Pathway Inhibitor
01/15/2009 - Curis Announces Genentech’s Initiation of Phase II Clinical Trial in Advanced Ovarian Cancer with Hedgehog Pathway Inhibitor
12/08/2008 - Curis Announces Collaborator Genentech’s License of Ex-U.S. Rights to GDC-0449 to Roche
11/13/2008 - Curis to Present at Lazard Capital Markets 5th Annual Healthcare Conference
11/13/2008 - Curis to Present at 10th Annual Rodman & Renshaw Healthcare Conference
11/04/2008 - Curis Reports Third Quarter 2008 Financial Results
10/28/2008 - Curis to Present at 19th Annual Oppenheimer Healthcare Conference
10/27/2008 - Curis to Present at 7th Annual BIO Investor Forum Conference
10/23/2008 - Curis Announces Preclinical Efficacy Data for CUDC-305 at EORTC-NCI AACR Symposium
10/23/2008 - Curis to Release Third Quarter 2008 Financial Results and Hold Conference Call on October 28, 2008
10/21/2008 - Curis to Present at First Annual Boston Biotech R&D Conference
10/16/2008 - Curis Announces GDC-0449 Phase II Ovarian Cancer Trial Design
08/28/2008 - Curis Announces Nature Publication Elucidating a Paracrine Mechanism of Action in Hedgehog-Expressing Tumors
08/27/2008 - Curis Announces Dosing of First Patient in Phase I Clinical Trial of CUDC-101
08/26/2008 - Curis to Present at Noble Financial
Capital Markets 5th Annual Equity Conference
08/11/2008 - Curis Reports Second Quarter 2008 Financial Results
07/30/2008 - Curis to Release Second Quarter 2008 Financial Results and Hold Conference Call on July 30, 2008
07/23/2008 - Curis Selects Hsp90 Inhibitor CUDC-305 as Development Candidate from Targeted Cancer Drug Development Platform
07/21/2008 - Curis Announces GDC-0449 Phase I Clinical Data Presented at American Society of Clinical Oncology Annual Meeting 2008
06/02/2008 - Curis to Present at Rodman & Renshaw
5th Annual Global Healthcare Conference
05/12/2008 - Curis Announces Genentech’s Initiation of Hedgehog Antagonist Phase II Clinical Trial In Metastatic Colorectal Cancer
05/05/2008 - Curis to Present at Deutsche Bank 33rd Annual Healthcare Conference
04/28/2008 - Curis to Release First Quarter 2008 Financial Results and Hold Conference Call on April 30, 2008
04/23/2008 - Curis Announces Preclinical Efficacy Data for CUDC-101 at AACR Annual Meeting 2008
04/14/2008 - Curis Announces GDC-0449 Phase I Clinical Data Presented at AACR Annual Meeting 2008
04/14/2008 - Curis announces presentations at American Association for Cancer Research Annual Meeting 2008
04/09/2008 - Curis Announces Presentation at the 235th American Chemical Society National Meeting
04/07/2008 - Curis Announces Phase II Clinical Plan for Hedgehog Antagonist Presented by Collaborator Genentech
03/14/2008 - Curis Announces Conclusion of Hedgehog Agonist Collaboration with Wyeth
03/10/2008 - Curis Reports Fourth Quarter and Year-End 2007 Financial Results
02/14/2008 - Curis to Release Second Quarter 2007 Financial Results and Hold Conference Call on February 14, 2008
02/07/2008 - Curis to Present at the BIO CEO & Investor Conference 2008
02/06/2008 - Curis, Inc. Announces Sale of its BMP-7 Assets to Stryker Corporation
12/28/2007 - Curis, Inc. Reports Decision to Advance a Systemically Administered Hedgehog Antagonist into Phase II Clinical Testing
12/12/2007 - Curis to Present at CIBC World Markets 18th Annual Healthcare Conference
11/02/2007 - Curis to Present at Acumen Biofin Rodman & Renshaw 9th Annual Healthcare Conference
10/31/2007 - Curis Reports Third Quarter 2007 Financial Results
10/30/2007 - Curis Announces Presentation at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
10/25/2007 - Curis to Release Third Quarter 2007 Financial Results and Hold Conference Call on October 30, 2007
10/23/2007 - Curis Announces Presentation at CHI’s “Discovery on Target: Developing Inhibitors for Promising Drug Targets” Conference
10/17/2007 - Curis, Inc. Announces Initiation of Expansion Cohort in Collaborator Genentech’s Phase I Clinical Trial of a Systemically Administered Hedgehog Antagonist
10/16/2007 - Curis to Present at BIO InvestorForum 2007
10/03/2007 - Curis Provides Program Update on Development Candidate CUDC-101 and its Targeted Cancer Drug Development Platform
09/25/2007 - Curis Updates Research on Hedgehog Agonist Protein Program for Cardiovascular Disease Indications
08/28/2007 - Curis to Present at the Noble Financial Small Cap Equity Conference
08/16/2007 - Curis Announces Agreement for $13 million Private Placement
08/06/2007 - Curis Reports Second Quarter 2007 Financial Results
07/31/2007 - Curis to Release Second Quarter 2007 Financial Results and Hold Conference Call on July 31, 2007
07/24/2007 - Curis Provides Update on BMP-7 Program
05/18/2007 - Curis Presentation Time at Acumen Biofin Rodman & Renshaw 4th Annual Global Healthcare Conference Changes to 8:40 a.m.
05/11/2007 - Curis to Present at Acumen Biofin Rodman & Renshaw 4th Annual Global Healthcare Conference
05/10/2007 - Curis Provides Update on Hedgehog Agonist Hair Growth Program
05/09/2007 - Curis Reports First Quarter 2007 Financial Results
05/02/2007 - Curis to Release First Quarter 2007 Financial Results and Hold Conference Call on May 2, 2007
04/25/2007 - Curis Announces Hedgehog and Wnt Antagonist Data Presentation at AACR
04/17/2007 - Curis to Present at CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference
04/11/2007 - Curis Selects First Development Candidate from its Targeted Cancer Drug Development Platform
03/14/2007 - Curis Reports Fourth Quarter and Year-End 2006 Financial Results
02/14/2007 - Curis to Release Year End and Fourth Quarter 2007 Financial Results and Hold Conference Call on February 14, 2007
02/01/2007 - Curis, Inc. Announces Dosing of First Patient in Hedgehog Antagonist Phase I Clinical Trial
01/31/2007 - Curis Announces Key Management Promotions
12/20/2006 - Curis to Present at Wall Street Analyst Forum Investor Conference
11/30/2006 - Curis Reports Third Quarter 2006 Financial Results
11/09/2006 - Curis to Present at Rodman & Renshaw’s 8th Annual Healthcare Conference
11/01/2006 - Curis to Present at CIBC World Markets 17th Annual Healthcare Conference
11/01/2006 - Curis to Release Third Quarter 2006 Financial Results and Hold Conference Call on November 9, 2006
10/31/2006 - Curis to Present at the Mass Opportunities Annual Investors Conference
10/30/2006 - Curis to Present at BIO Investor Forum 2006
10/13/2006 - Curis, Inc. Announces Genentech Filing of Investigational New Drug Application for Systemic Administration of a Hedgehog Antagonist
10/05/2006 - Curis Issued U.S. Patent Covering Hedgehog Pathway Agonists
10/04/2006 - Curis, Inc. Agrees to Settlement with Micromet AG
10/03/2006 - Curis to Present at Noble Financial’s Small Cap Conference and Micro Cap Symposium, Titled ‘OnTrack 2006’
09/21/2006 - Curis, Inc. Augments Scientific Advisory Board with Leaders in Cancer Research and Development
09/18/2006 - Curis, Inc. Named One of New England’s Fastest Growing Life Sciences Companies in Deloitte’s Technology Fast 50 Program
09/14/2006 - Curis, Inc. Announces New Cancer Programs, Formation of China-Based Subsidiary
09/12/2006 - Curis Determines to Opt Out of Co-Development of Basal Cell Carcinoma Drug Candidate
09/01/2006 - Curis Reports Second Quarter 2006 Financial Results
07/27/2006 - Curis to Release Second Quarter 2006 Financial Results and Hold Conference Call on July 27, 2006
07/18/2006 - Curis Provides Update on Basal Cell Carcinoma Phase I Clinical Trial; Parties Determine to Halt Phase I Trial
07/11/2006 - Hedgehog Pathway Activation Promotes Coronary Growth; Preclinical Data Published in Genes & Development
06/22/2006 - Curis Issued U.S. Patent Covering Drug Discovery Assays
06/13/2006 - Curis Initiates Strategic Plan Focused on Later-Stage Drug Development
06/08/2006 - Topical Hedgehog Agonist Accelerates Wound Healing in Diabetes
05/23/2006 - Hedgehog Antagonist Data Presented at Australasian College of Dermatologists Scientific Meeting
05/16/2006 - Genentech Funds Additional Hedgehog Research at Curis; Update on Phase I Basal Cell Carcinoma Trial
05/09/2006 - Curis Reports First Quarter 2006 Financial Results
05/09/2006 - Curis to Release First Quarter 2006 Financial Results and Hold Conference Call on May 9, 2006
05/02/2006 - Curis Announces Hedgehog Antagonist Data Presentation at AACR
04/03/2006 - Curis to Present at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference
03/27/2006 - Curis Reaches First Preclinical Milestone in Hair Growth Program with Procter & Gamble
03/21/2006 - Curis to Restate Certain Prior Periods
03/17/2006 - Curis Reports Fourth Quarter and Year-End 2005 Financial Results
02/14/2006 - Curis to Present at the BIO CEO & Investor Conference 2006
02/08/2006 - Curis to Release 2005 Year-End Financial Results and Hold Conference Call on February 14, 2006
02/01/2006 - Curis to Present at the Brean Murray Small Cap Institutional Investor Conference
01/26/2006 - Curis Provides Update on Ongoing Basal Cell Carcinoma Phase I Clinical Trial
01/23/2006 - Curis Announces Expansion of Relationship with Centocor Research & Development, Inc.
12/15/2005 - Curis Announces Receipt of Extended Funding from Wyeth
11/21/2005 - Curis Reports Third Quarter 2005 Results
11/14/2005 - Curis to Release 2005 Third Quarter Financial Results on November 14, 2005
11/11/2005 - Curis Announces Delay in Filing Form 10-Q for Third Quarter of Fiscal 2005
11/09/2005 - Curis to Present at CIBC World Markets 16th Annual Healthcare Conference
11/03/2005 - Curis to Release 2005 Third Quarter Financial Results on November 9, 2005 and Hold Conference Call on November 10, 2005
10/31/2005 - Curis to Present at Rodman & Renshaw 7th Annual Healthcare Conference
10/27/2005 - Hedgehog Pathway Activation Promotes Tissue Protection and Repair in Cardiac Ischemia
10/25/2005 - Curis to Present at MASS Opportunities Conference
10/25/2005 - Curis Announces the Receipt of Second Extension of Funding from Genentech
10/13/2005 - Curis to Present at the BIO InvestorForum 2005
10/12/2005 - Curis to Present at the UBS 2005 Global Life Sciences Conference
09/20/2005 - Curis and Procter & Gamble Enter into R&D Agreement for Hair Growth Program
09/19/2005 - Hedgehog Agonists Modulate Hair Growth; Preclinical Data Published in The Journal of Investigational Dermatology
09/01/2005 - Curis to Present at the 2005 Bear Stearns Healthcare Conference
08/31/2005 - Curis CEO, Daniel Passeri, to Preside Over NASDAQ Closing Bell on August 16, 2005
08/15/2005 - Curis Reports Second Quarter 2005 Results
08/09/2005 - Curis to Present at the America's Growth Capital Conference
07/27/2005 - Curis to Present at the Bear Stearns Boston Biotech Confab
06/23/2005 - Curis Announces Dosing of First Patient in Phase I Clinical Trial for Basal Cell Carcinoma
06/08/2005 - Curis to Present at the Needham Biotechnology Conference
05/18/2005 - Curis to Present at UBS Global Pharmaceuticals Conference
05/17/2005 - New Report Suggests Hedgehog Pathway Stimulation Improves Wound Healing in Diabetic Wound Model
05/09/2005 - Curis Announces U.S. Food and Drug Administration Acceptance of Application to Initiate Skin Cancer Phase I Clinical Trial
05/04/2005 - Curis Reports First Quarter 2005 Results
04/26/2005 - Curis Announces Reports of New Cancers Linked to Abnormal Hedgehog Pathway Signaling
04/21/2005 - Curis Receives Extended Cancer Program
04/14/2005 - Curis to Release 2005 First Quarter Financial Results and Hold Conference Call on April 26, 2005
04/13/2005 - Curis Announces Second Major Collaboration with Genentech
04/04/2005 - New Report Demonstrates BMP-7 Prevents Two Metabolic Disorders Associated with Chronic Kidney Disease
03/09/2005 - Curis Issued U.S. Patent Covering Methods for Treating Chronic Kidney Disease
03/02/2005 - Curis Presents Study Showing Stimulation of Hair Growth by Small Molecule Hedgehog Pathway Agonist
02/22/2005 - Curis to Co-Develop Cancer Drug with Genentech in the United States
02/01/2005 - BMP-7 Promotes Regeneration of Injured Kidneys in Preclinical Model of Renal Disease; BMP-7, discovered by Curis, demonstrates potential as therapeutic agent to treat kidney disease
01/11/2005 - Report of Hedgehog Pathway Efficacy in Preclinical Model of Parkinson's Disease
12/17/2004 - Hedgehog Pathway Restores Cardiac Function in Preclinical Models of Heart Attack
11/10/2004 - BMP-7 Reverses Vascular Calcification in a Preclinical Model of Chronic Kidney Disease
11/01/2004 - New Reports of Positive Preclinical Results using Small Molecule Hedgehog Agonists
10/25/2004 - Hedgehog Pathway Linked to Advanced Stages of Prostate Cancer
10/20/2004 - Compound Eradicates Brain Tumor in Preclinical Cancer Model
09/21/2004 - Hedgehog Signaling Promotes Blood Vessel Development and Restores Nerve Function
09/20/2004 - Hedgehog Pathway Implicated in Cancer Metastasis; Report Links Elevated Levels of Hedgehog Signaling to Most Lethal Form of Prostate Cancer
09/13/2004 - Hedgehog Signaling Pathway is New Therapeutic Target for Breast Cancer
09/08/2004 - Curis Receives $5.4 Million Grant from Spinal Muscular Atrophy Foundation
09/07/2004 - Inhibitors of Hedgehog Signaling Pathway Block Growth of Prostate Cancer Cells; Preclinical report suggests new therapeutic approach to treatment of prostate cancer
08/25/2004 - Hedgehog Pathway is Essential for Blood Vessel Development; Study Demonstrates Crucial Role of Hedgehog Signaling Pathway in Development of the Vascular Network
08/23/2004 - Curis Issued U.S. Patent Covering Method for Treating Stroke
07/29/2004 - Compound Discovered by Curis Promotes Development of Motoneurons
06/16/2004 - New Reports of Cancers Linked to Abnormal Hedgehog Pathway Signaling
06/09/2004 - Curis Collaboration with Wyeth Highlighted in Current Issue of BusinessWeek Magazine; Collaboration Seeks to Develop Treatments for Damaged Brain Tissues
05/18/2004 - Curis Collaboration with Project A.L.S. Highlighted in Current Online Issue of Fortune Magazine
05/05/2004 - Curis Issued U.S. Patent Covering Methods of Treating Motor Neuron Disorders such as Spinal Cord Injury and ALS
04/22/2004 - BMP-7, a Compound Discovered by Curis, Promotes Repair of Injured Kidneys and Reduces Fibrosis in Preclinical Models
03/04/2004 - BMP-7 Prevents Bone Disease in a Model of Chronic Kidney Failure
02/09/2004 - Curis Issued U.S. Patent Covering Methods to Inhibit Hedgehog Pathway and Prevent the Growth of Certain Cancers
02/05/2004 - Curis Issued U.S. Patent Covering Methods to Inhibit Hedgehog Pathway and Prevent the Growth of Certain Cancers
02/04/2004 - Curis Issued U.S. Patent Covering Hedgehog Pathway Agonists
01/27/2004 - Curis Announces Strategic Partnership with Wyeth Pharmaceuticals to Develop Therapeutics for Neurological Disorders
01/12/2004 - Curis Issued U.S. Patent on Method for Promoting Hair Growth
10/28/2003 - Curis to Release First Quarter 2012 Financial Results and Hold Conference Call on May 8, 2012
11/30/-1
